In Vivo CAR-T Therapies—A New Era of Programmable Immunity
International Journal of Molecular Sciences · 11.02.2026 · 27 (4) · 1737
DOI: 10.3390/ijms27041737 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.02.2026. Verfasst von Stefano Pierini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Independent Researcher, Philadelphia, PA 19342, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 252 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ex vivo chimeric antigen receptor (CAR) T cell therapies have achieved remarkable clinical success over the past decade, enabling effective treatment of several hematologic malignancies once considered incurable. However, their broader use remains limited. Barriers include complex and costly manufacturing, long production timelines, and risk of significant side effects and toxicities, challenges that have been further exacerbated by the reduced investment across the biotech sector since 2022. Emerging in vivo CAR-T approaches seek to overcome many of these limitations by generating CAR-T cells directly within the patient, most commonly using lentiviral or lipid nanoparticles (LNPs) delivery vectors. This strategy has the potential to streamline production, allow more tunable and repeatable dosing, and markedly reduce overall costs. However, it also raises new questions regarding genomic safety, the specificity and durability of CAR expression, host immune responses, pharmacokinetics, and regulatory oversight. In this review, we summarize the major and emerging in vivo CAR-T delivery platforms—analyzing their underlying technology, preclinical and clinical performance, and developmental paths—and discuss the scientific, technical, and biological challenges shaping this rapidly emerging field. We further outline future directions and opportunities in the field of programmable T cell immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Independent Researcher, Philadelphia, PA 19342, USA.
- 100XBIO, Inc., Stoneham, MA 02180, USA.
- Division of Transplant Immunology, Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
ORCID-Profile: Stefano Pierini, Sergei Pustylnikov, Tatiana Akimova
Zitieren
APA
Pierini, S., Qureshi, R., Pustylnikov, S., Bartosh, Z., & Akimova, T. (2026). In Vivo CAR-T Therapies—A New Era of Programmable Immunity. International Journal of Molecular Sciences, 27(4), 1737. https://doi.org/10.3390/ijms27041737
Vancouver
Pierini S, Qureshi R, Pustylnikov S, Bartosh Z, Akimova T. In Vivo CAR-T Therapies—A New Era of Programmable Immunity. International Journal of Molecular Sciences. 2026;27(4):1737. doi:10.3390/ijms27041737
BibTeX
@article{Pierini2026,
author = {Pierini, Stefano and Qureshi, Rehman and Pustylnikov, Sergei and Bartosh, Zhanna and Akimova, Tatiana},
title = {In Vivo CAR-T Therapies—A New Era of Programmable Immunity},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {4},
pages = {1737},
doi = {10.3390/ijms27041737}
}
EUVIMED